| Ninlaro (ixazomib) / Takeda |
NCT03416374: A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy |
|
|
| Completed | 4 | 45 | Japan | Ixazomib, Bortezomib, Carfilzomib, Lenalidomide, Dexamethasone | Takeda | Relapsed and/or Refractory Multiple Myeloma | 05/21 | 05/21 | | |
NCT04217967: Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients |
|
|
| Recruiting | 4 | 180 | RoW | Ixazomib, Lenalidomide | Peking Union Medical College Hospital, Peking University Third Hospital, Beijing Jishuitan Hospital, Beijing Chao Yang Hospital, Xuanwu Hospital, Beijing, Peking University First Hospital, Jilin Provincial Tumor Hospital, Second Hospital of Shanxi Medical University, The First Affiliated Hospital of Shanxi Medical University, Tianjin Medical University General Hospital, The First Affiliated Hospital of Anhui Medical University | Multiple Myeloma | 10/22 | 10/22 | | |
ChiCTR2100045236: A real-world observational clinical study of Ixazomib in the treatment of multiple myeloma patients with functional constipation |
|
|
| Recruiting | 4 | 50 | | No | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Not involved | multiple myeloma | | | | |
ChiCTR2000029863: A multicenter, prospective, randomized, study for Ixazomib plus Cyclophosphamide and Dexamethasone compared with Lenalidomide plus Cyclophosphamide and Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma |
|
|
| Not yet recruiting | 4 | 172 | | Ixazomib plus Cyclophosphamide and Dexamethasone ;Lenalidomide plus Cyclophosphamide and Dexamethasone | Ruijin Hospital Shanghai Jiaotong University School of Medicine; Ruijin Hospital Shanghai Jiaotong University School of Medicine, raise independently | Multiple myeloma | | | | |
ChiCTR2100054121: A multicenter, open, prospective, single-arm clinical study of ixazomib/pomalidomide/dexamethasone (IxaPD) in the treatment of patients with first relapsed multiple myeloma |
|
|
| Not yet recruiting | 4 | 60 | | Ixazomib 4 mg orally; pomalidomide 4 mg orally; dexamethasone 40 mg orally [for patients over 75 years old, the dose of dexamethasone is reduced to 20 mg, and the cycle remains unchanged; 28 days is a cycle. | Henan Cancer Hospital; Henan Cancer Hospital, Self-financed | Multiple myeloma | | | | |
NCT05722405: Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma |
|
|
| Recruiting | 4 | 100 | RoW | Ixazomib plus low-dose lenalidomide, Ixazomib | Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Lishui Country People's Hospital, Dongyang People's Hospital, Shangyu People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital | Multiple Myeloma | 06/24 | 07/25 | | |
HS-2883, NCT04989140: Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide |
|
|
| Recruiting | 4 | 60 | RoW | Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone | Peking Union Medical College Hospital, Beijing Jishuitan Hospital, Beijing Chao Yang Hospital, Tianjin Medical University General Hospital, The First Affiliated Hospital of Zhengzhou University, Peking University Third Hospital, Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, Second Hospital of Shanxi Medical University, The First Affiliated Hospital of Dalian Medical University, The Second Affiliated Hospital of Harbin Medical University, Tianjin Medical University Cancer Institute and Hospital, First Hospital of China Medical University | Multiple Myeloma | 07/24 | 07/24 | | |
ChiCTR2000038062: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy with bortezomib, lenalidomide and dexamethasone (BRd) in newly diagnosed elderly multiple myeloma |
|
|
| Recruiting | 4 | 100 | | BRd+IRd+IR | The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised | Multiple Myeloma | | | | |
ChiCTR2000038075: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy of bortezomib, lenalidomide and dexamethasone (BRd) with newly diagnosed young multiple myeloma |
|
|
| Recruiting | 4 | 150 | | BRd+/-ASCT+IRd+IR | The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised | Multiple Myeloma | | | | |
US MM-6, NCT03173092: A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) |
|
|
| Active, not recruiting | 4 | 141 | US | Ixazomib, NINLARO, MLN9708, Lenalidomide, Dexamethasone | Takeda | Multiple Myeloma | 11/26 | 11/26 | | |
US MM-7, NCT05183139: A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma |
|
|
| Withdrawn | 4 | 0 | NA | Ixazomib, NINLARO, Pomalidomide, POMALYST, Lenalidomide, REVLIMID, Dexamethasone | Takeda | Multiple Myeloma | 12/26 | 12/26 | | |
